General Information of Drug Combination (ID: DCAAE55)

Drug Combination Name
DFN-15 Hepzato
Indication
Disease Entry Status REF
Lung adenocarcinoma Investigative [1]
Component Drugs DFN-15   DM3BF9B Hepzato   DM2AZPP
N.A. N.A.
High-throughput Screening Result Testing Cell Line: MDA-MB-231
Zero Interaction Potency (ZIP) Score: 4.9
Bliss Independence Score: 11.87
Loewe Additivity Score: 10.72
LHighest Single Agent (HSA) Score: 9.97

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Carcinoma DCOM1GF RXF 393 Investigative [4]
Adenocarcinoma DC6352A OVCAR3 Investigative [1]
Adenocarcinoma DC52MGE HT29 Investigative [1]
------------------------------------------------------------------------------------

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
4 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165